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LABORATORY STUDY
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ABSTRACT
Uncontrolled activation of transforming growth factor beta (TGF-b) family members is hypothe-
sized to participate in type 2 diabetes (T2D) dependent diabetic nephropathy (DN). We evaluated
and compared downstream activation of the Smad2-signaling pathway in kidney samples from
T2D patients to kidneys from the T2D model of leptin receptor deficient db/db mouse.
Furthermore, expression of TGF-b family members was evaluated to elucidate molecular mecha-
nisms in the mouse model. Kidney samples from patients with advanced stages of DN showed
elevated pSmad2 staining whereas db/db mouse kidneys surprisingly showed a decrease in
pSmad2 in the tubular compartment. Structurally, kidney tissue showed dilated tubules and
expanded glomeruli, but no clear fibrotic pattern was found in the diabetic mice. Selective TGF-b
family members were up-regulated at the mRNA level. Antagonists of bone morphogenetic pro-
tein (BMP) ligands, such as Gremlin1, USAG1 and Sclerostin, were strongly up-regulated suggest-
ing a dampening effect on BMP pathways. Together, these results indicate a lack of translation
from T2D patient kidneys to the db/db model with regards to Smad signaling pathway. It is
plausible that a strong up-regulation of BMP antagonizing factors account for the lack of Smad1/
5/8 activation, in spite of increased expression of several BMP members.
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Metabolic diseases such as obesity and type 2 diabetes
(T2D) are closely linked, and 35% of the population is
estimated overweight or obese in the Western world, a
number which continues to increase [1]. Obesity and
T2D are associated with a higher risk of cardiovascular
disease (CVD), decreased insulin sensitivity and chronic
kidney disease (CKD), which increases mortality beyond
the traditional CVD risk factors [2,3]. Obesity-related
renal disease is similar to the microvascular damage
observed in diabetic nephropathy (DN) [4]. It is believed
that kidney damage is a consequence of a combination
of increased glomerular capillary pressure and hyperfil-
tration, endothelial cell proliferation and dysfunction,
increased vascular permeability, increased protein traf-
fic, mesangial hyperplasia and renal hypertrophy [5,6].
T2D accounts for more than 90% of the worldwide
diabetes incidence, but DN in T2D patients is less well
described than T1D patients [7]. T2D patients show
larger variation in disease pattern and pathology, which
complicates the study of DN within T2D as estimates for
rate of disease progression are imprecise and sparse
[8–10].
DN is the leading cause of CKD where a hallmark is
the development of kidney fibrosis. The Transforming
Growth Factor beta (TGF-b) family has been implicated
in kidney fibrogenesis evidenced by elevated TGF-b iso-
forms and increased Smad signaling. These findings are
also seen in obese patients and animal models [11–13].
However, the specific role of Smad2 in DN remains
unknown.
Patients with DN show increased TGF-b1 mRNA and
protein levels in the glomerular and tubulointerstitial
compartments [14,15]. Additionally, in vitro cell culture
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experiments demonstrate that hyperglycemia stimu-
lates TGF-b1 production from glomerular and tubuloin-
terstitially derived cells [16–21].
Late stages of DN show glomerulosclerosis with
Kimmelstein–Wilson nodules, tubulointerstial fibrosis,
thickening of the basement membrane, albuminuria
and decline of renal function [22], but no current
experimental model is able to fully recapitulate these
renal changes. The db/db mouse model shows signifi-
cant obesity early in life, followed by mesangial
expansion, thickening of the glomerular basement
membrane (GBM) and proteinuria [23,24]. The model
shows hyperlipidemia, obesity, albuminuria, mesangial
matrix expansion and immune compromisation
[25–27]. Albuminuria is seen at 10–12weeks, and by
week 20, the mice show overt proteinuria and
advanced kidney structural damage [25]. Development
of diabetes is more severe in the C57BL/KsJ mice
compared to the C57BL/6 J mice [28], which is the
reason for us using the KsJ strain.
In the current study, we evaluated the similarities
and differences in renal compartmental phospho-
Smad2 levels between human T2D associated DN and
T2D DN mouse model (db/db) to determine how well
the disease translates between the species. We further
explored mouse TGF-b family expression and activity of
the TGF-b counterbalancing Smad1/5/8 pathway to
give a mechanistic insight in to the observed species
differences. Our data suggest a clear lack of translation
between patients and mouse model with regards to
TGF-b family induced Smad signaling.
Methods
Animal models
Male db/db mice (Strain C57BL/KsJ from Charles River,
Germany) were purchased at 6–8weeks of age and kept
according to standard rules at the Novo Nordisk A/S
animal facility (Måløv, Denmark). All experiments were
approved by the Danish Ethical Committee. Blood glu-
cose was measured by tail vein blood puncture and dia-
betes defined as three consecutive morning blood
glucose readings of >16mmol/L using Glucose Analyzer
Biosen 5040 (Germany). HbA1c% (percentage glycated
haemoglobulin) was measured using Cobas 6000
(Switzerland). Albumin in the urine was measured by an
enzyme-linked immunosorbent assay (ELISA) kit from
Bethyl Labs (USA).
At 15 and 23weeks of age, the mice were anesthe-
tized, sacrificed and cardiac perfused before the kidneys
were isolated for histology and gene expression
analysis.
Histology and immunostaining
Human kidneys were obtained from deceased patients
from autopsy material at the Pathology Department at
Leiden University Medical Center and stained at this
facility. Cause of death was examined by regular path-
ology. Some kidney samples were obtained from
patients that had been selected for organ transplant-
ation. If the patients were eligible for transplantation
their organs were prepared by post mortem perfusion
of the whole body intravenously with University of
Wisconsin fluid. The body was cooled and biopsies of
the kidneys were taken for pre-transplant histological
analysis. If their kidneys were unsuitable for transplant-
ation because either the ureter or the renal artery were
too short, these kidneys were made available for
research as control kidneys. If DN was found in donor
kidneys by histology, this also disqualified the kidneys
for transplantation and these were also made available
for research. Clinical symptoms for T2D with DN
included polyuria, thirst, hypertension, blurred vision,
albuminuria and increased level of serum creatinine
according to UK National Health Service. The human
experiments are all in agreement with the Declaration
of Helsinki and samples were handled anonymously in
accordance with the Dutch National Ethics Guidelines
(Code for Proper Secondary Use of Human Tissue,
Dutch Federation of Medical Scientific Societies) mean-
ing that experiments were approved by the institutional
ethics board of the LUMC. Kidneys were classified posi-
tive for DN by the histopathological classification [29].
The T2D patients in this study only showed DN and not
prevalence of other non-diabetic renal disease. All T2D
patients had been on angiotensin-converting enzyme
inhibitors, which is standard treatment for T2D in the
Netherlands. Glomerular filtration rate (GFR) stage was
classified by the Kidney Disease Improving Global
Outcomes work groups KDIGO [30]. Control kidneys
were processed similar to the diabetic kidneys and
mouse kidneys by fixation in buffered formalin, process-
ing, paraffin embedment and cut at 4-mm. Antigen-
retrieval was done by citric acid buffer (0.01M, pH 6.0)
at 100 C in a microwave oven for 10min. Slides were
cooled at room temperature (RT) for 20min. Sections
for immunostaining were incubated for 20min with
0.3% H2O2 in absolute methanol to quench endogenous
peroxidase activity. Blocking took place at RT using
phosphate buffered saline (PBS) containing 0.1% BSA
and 5% goat serum (Dako). Human and mouse slides
were incubated overnight at 4 C with primary poly-
clonal rabbit antisera pSmad2 diluted in PBS with 1%
BSA in a dilution of 1:100 (a concentration of 14ug/ml
total protein) (described in [31–33]). This antibody is
630 L. H. THOMSEN ET AL.
specific to phosphorylated Smad2 and does not cross-
react to other phosphorylated Smads on immunopreci-
pitation [33]. Mouse slides were also incubated with
primary polyclonal rabbit antibody pSmad1/5/8 (#9511,
Cell Signaling) diluted in PBS with 1% BSA in a 1:100
dilution (concentration of 14 ug/mL) overnight at 4 C.
Normal rabbit serum diluted to the same concentration
worked as negative control. After 3x5-min washes in
PBS, the slides were incubated for 30min with HRP-con-
jugated anti-rabbit EnVision (#K4002, Dako) at RT. After
3x5-min washes in PBS the antibody complexes were
visualized using EnVisionþ System-HRP (DAB) (#K4011,
Dako). Slides were counterstained with hematoxylin,
then dehydrated and mounted. The degree of anti-
pSmad immunostaining was scored independently by
two individuals in a blinded fashion and separately in
areas of glomeruli, proximal tubular cells (PTECs) and
distal tubular cells (DTECs). For the mouse tissue, the
expression within the glomeruli was quantified by per-
cent positive nuclei/total nuclei in 20 glomeruli per kid-
ney. Degree of staining of both PTECs and DTECs was
done by grading the degree of positive nuclei staining
from 0–3 in the whole tissue for each structure. The
human tissue was also graded 0–3. It was noted
whether staining was in the Bowman’s capsule, nuclear
or cytoplasmic.
Sections for analysis of morphological changes were
stained for hematoxylin and eosin (H&E), Periodic Acid-
Schiff (PAS) and Picrosirius red. Morphometric analysis
of glomeruli and tubular lumen size was measured
manually in Phillips viewer program. Glomerular area
was measured by drawing the circumference around
the glomerular capillary tuft (without Bowman’s cap-
sule). An average of 20 glomeruli was examined per
mouse. Distal tubulus lumen diameter was examined by
measuring the perpendicular line between the base-
ment membranes within the tubular lumen. An average
of 70 tubules was measured per mouse.
Analysis of mRNA
Kidney homogenates in Trizol were made by use of the
TissueLyser II system (Qiagen). mRNA was isolated with
a RNeasy Mini kit (#74106, Qiagen) and reverse tran-
scribed according to the manufacturer’s instructions.
Gene expression analysis by TaqMan Microfluid card
with predefined primer sets was performed by quantita-
tive real-time PCR and cycle threshold (Ct) values of the
gene targets were normalized to the average of
four housekeeping genes (18 S, Ribosomal Protein
L27(Rpl27), Ribosomal Protein S13 (Rps13) and
Ubiquitin C (UBC)) found unchanged in the kidney. Fold
change in expression of target genes compared with
the control reference group was calculated using rela-
tive quantitation of gene expression by the 2-DDCT
method recommended by Applied Biosystems. Qlucore
Omics Explorer 3.2 (Qlucore, Lund, Sweden) was used
to analyze 44 genes (Ct(target) – Ct(average of ref
genes)) and create a heat-map ranking the genes based
on p values when comparing db/db to db/þ. To avoid
false positive significance the false discovery rate was
set to <.05 corresponding to a p values considered
significant when <.024.
AlphaLISA SureFire ultra pSmad1 assay
The mouse PTEC cell line TCMK1 (#CCL-139TM, ATCCVR )
was seeded at a density of 10.000 cells/well in 96 well
plates for 24 h. Recombinant Gremlin1 (#956-GR, R&D
Systems) was pre-incubated with 4 ng/mL BMP-4 (and
150 ng/mL BMP-7, equivalent to EC80) for 15min. This
mixture was added to the PTECs for 90min at 37 C,
5%CO2 and 5%O2. Cells were lysed with a 1x lysis buffer
from the SureFire Ultra kit (#ALSU-PSM1-A500,
PerkinElmer) and handled according to the man-
ufacturer’s instructions. Light emission in the sample
correlates to the quantity of pSmad1 protein. The plate
was read on an EnVision Wallac, PerkinElmer.
Statistical analysis
Biochemical and structural measurements were com-
pared by unpaired unequal variances t-test (Welch’s
t-test) (two-tailed).
Difference in pSmad immunostaining was tested by
an unpaired, nonparametric Mann-Whitney (two-tailed)
test. This was chosen as the scoring values do not rep-
resent normally distributed data.
The gene expression data are shown as fold changes
(Box and whiskers with range). Target genes were com-
pared with the control reference group using the 2-DDCT
method. Statistics were calculated using the delta-Ct
values for an unpaired unequal variances t-test (Welch’s
t-test) (two-tailed).
For all tests, except gene expression, p< .05 was con-
sidered significant. Statistical analyses were performed
using GraphPad Prism 5 (GraphPad software Inc.,
San Diego, CA).
Results
T2D nephropathy is associated with an increased
glomerular and tubular cytoplasmic pSmad2
signature
DN associated fibrosis is considered to involve an imbal-
ance of the TGF-b family activity causing elevated
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pSmad2 signaling in diabetic patients [12,13]. We per-
formed an in-depth immunohistochemical evaluation of
kidneys from DN classified T2D patients to determine
how the signaling signature of pSmad2 was altered
compared to healthy control kidneys. Diabetic kidneys
were classified stage 2B and 3 of DN and had a GFR
60 (Table 1). Blood pressure and gender distribution
were similar between controls and patients, while the
patients showed a higher average age than controls
(Table 1).
Glomerular cells of healthy subjects showed a low
nuclear expression of pSmad2 mainly in the Bowman’s
capsule (Figure 1(A)): whereas in diabetic patients the
glomerular cells were enlarged due to sclerosis and
showed an overall elevated cytoplasmic and nuclear
pSmad2 staining (Figure 1(B,C)). The expression of
pSmad2 within the glomeruli in the T2D patients
showed a higher degree of heterogeneity (cytoplasmic
and nuclear) compared to what was observed within
the glomeruli of the healthy subjects (Figure 1(A–C)). In
general, kidneys from the healthy subjects showed clear
nuclear staining primarily localized within the parietal
cells of the Bowman’s capsule and little cytoplasmic
activation, while the DN kidneys showed an overall
increased cytoplasmic pSmad2 expression.
The PTECs were pSmad2 negative in the healthy kid-
neys whereas the DTECs showed a variation from low
to moderate nuclear staining of pSmad2 (Figure 1(A,C)).
Diabetic tubuli showed a variation in pSmad2 staining
in samples from diabetic patients (Figure 1(C)).
Importantly, a small increase in PTECs and moderately
elevated pSmad2 levels within the DTECs were
observed in the DN subjects (Figure 1(B,C)). The ele-









Healthy 3 * 0 2 #
Healthy 1 * 0 2 O
Healthy 2 * 0 2 O
Healthy 2 * 0 2 O#
T2D 1 # 2 # 3 #
T2D 1 O# 0 1 O
T2D 1 O# 1 # 3 O#
T2D 2 O# 1 # 3 O#
* Positive staining only in Bowman’s capsule (parietal 
epithelium)
O nuclear staining, # cytoplasmic staining
(C)
Figure 1. pSmad2 immunostainings of T2D patients vs. controls. pSmad2 immunostaining of kidneys from T2D patients compared
to healthy donor kidneys. Representative IHC sections from a healthy donor kidney (A) and a T2D patient kidney (B) shown at
20X magnification where the black-line ¼50uM. Kidney sections show a glomerulus structure (dotted arrow), a proximal tubule
(arrow connected to a diamond) and a distal tubule (diamond connected to diamond). Filled triangle indicates positively stained
nuclei structure indicative of active signaling.















T2D 85 Female Accident 3 5 11 206 110/70
T2D 69 Male – 3 3 47 81 –
T2D 75 Male Pneumonia 2B 2 60 71 130/60
T2D 88 Female Shock 2B 4 20 331 120/75
Ctrl 1 41 Male Aneurysm – – – 184 122/87
Ctrl 2 74 Female Sub arachnoid bleeding – – – 58 155/65
Ctrl 3 68 Male Cardiac arrest – – – 85 140/78
Ctrl 4 40 – Sub arachnoid bleeding – – – – –
Clinical data of T2D patients with DN and control subjects. DN histopathological classification by Tervaert et al. 2010 [29]. GFR classification by KDIGO
2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease [30].
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compartment was as in the glomeruli mostly associated
with increased cytoplasmic levels and showed a higher
individual variation compared to the healthy kidneys.
Taken together, an elevated cytoplasmic pSmad2 sig-
nature was present in both the glomerular structures
and in the tubular compartment in diabetic kidneys.
These results suggest that a disease-related TGF-
b-family induced pSmad2 signaling signature is present
in T2D DN, but mostly associated with cytoplasmic
localization.
Significantly increased glomeruli size and
expanded lumen in distal tubules in db/db
diabetic mice with minimal fibrotic signature
The poor translation in pathology from mouse models
to patients within progressive renal disease has hin-
dered development of novel treatment regimens [34].
In this study we used db/db mice on a more severe dia-
betes prone background, the C57BL/KsJ. The diabetic
db/db mice showed significantly increased weight and
HbA1c compared to db/þmice (Table 2), while differ-
ence in kidney weight was minimal compared to
healthy mice. Furthermore, the diabetic animals showed
a strong and significant induction of albuminuria
(Table 2).
Histological evaluation showed that the diabetic
mice had structural differences with significantly ele-
vated glomeruli circumference (p< .0001) on H&E stain-
ing (Figure 2(A,B)) and Periodic acid-Schiff (PAS)
staining (Figure 2(E,F,I)). Intriguingly, no fibrotic profile
determined by collagen deposits measured by
Picrosirius red was observed in the diabetic db/db kid-
neys either in the glomeruli or in the tubular space
(Figure 2(C,D)) at 23weeks of age. However, the diam-
eter particularly of distal tubuli lumen increased in the
db/db mice compared to non-diabetic db/þ controls
(p¼ .001) (Figure 2(G,H,J)).
Taken together, the results show that despite having
enhanced HbA1c and albuminuria, the db/db mice did
not show a collagen-rich fibrotic profile. However,
the diabetic db/db kidney showed obvious tissue
re-modeling with enlarged glomeruli and distal tubuli
lumen present.
Nuclear pSmad2 translocation is reduced in db/db
proximal tubuli cells
Based on the absence of classical fibrotic patterns but
clear signs of tissue re-modeling similar to the human
DN subjects, the pSmad2 signature was determined by
immunohistochemistry in the db/db mice.
Overall, both healthy db/þ and diabetic db/db kid-
neys showed a diffuse staining pattern of pSmad2
throughout the whole kidney (Figure 3(A,B)). Detailed
analysis of the glomeruli from db/þ kidneys revealed a
moderate expression of pSmad2 with individual cells
showing nuclear pSmad2 translocation (Figure 3(C)).
Most interestingly, a clear tendency towards an overall
decreased pSmad2 expression with reduced frequency
of nuclear translocated pSmad2þ cells in diabetic glo-
meruli compared to healthy glomeruli was detected
(Figure 3(C–E)).
Healthy PTECs showed a moderate expression of
pSmad2 with a number of cells showing nuclear
pSmad2 translocation (Figure 3(F)). Similar to the glo-
meruli, diabetic PTECs showed reduced overall expres-
sion and significantly (p¼ .0097) reduced nuclear
pSmad2 translocation compared to healthy control
mice (Figure 3(F–H)).
DTECs in healthy kidneys showed a moderate expres-
sion of pSmad2 with a few cells expressing nuclear
translocated pSmad2 (Figure 3(I–K)). The pSmad2
expression signature and level was similar in the dia-
betic db/db DTEC as in the healthy db/þDTEC (Figure
3(I–K)).
Taken together, surprisingly both diabetic db/db glo-
meruli and PTECs showed a decreased expression and
nuclear translocation of pSmad2 compared to healthy
kidneys suggesting attenuated TGF-b family member
signaling in the db/db-T2D kidney.
No difference in pSmad1 signaling in diabetic
kidneys from db/db mice
The pSmad1/5/8 pathway has been shown to counter-
balance the TGF-b induced pSmad2 pathway, and is
activated by BMPs that are known to participate in kid-
ney homeostasis [35]. In order to determine the
pSmad1 signaling signature in kidneys of diabetic db/
db and healthy db/þmice a pSmad1/5/8 immunohisto-
chemiocal analysis was performed.
A very weak staining with only a few positive stained
cells of the glomeruli cells in the non-diabetic kidney
was observed. Nuclear translocation in the glomeruli
Table 2. Characteristics of db/db and db/þmice.
db/þ CTRL (n¼ 11) db/db (n¼ 17)
Weight (g) 32.40 ± 0.48 54.58 ± 1.75
Kidney (g) 0.22 ± 0.01 0.24 ± 0.00
HbA1c (%) 4.29 ± 0.04 8.52 ± 0.29
Albuminuria (mg/24 h) 79.81 ± 20.30 892.2 ± 77.40
Biochemical data on db/db mice vs. control db/þ. Animals for IHC were
23weeks of age. Table show weight, kidney weight, HbA1c and albumin-
uria. Values are shown as the mean ± SEM for each group. Values are
means ± SEM.
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Figure 2. Structural changes in non-diabetic db/þ compared to diabetic db/db kidneys. H&E staining of db/þ (A) and db/db (B)
mouse kidney. Picro-sirius red staining of db/þ (C) and db/db (D) mouse kidney. Periodic acid–Schiff staining of db/þ (E) and
db/db kidney tissue (F) with magnification of a representative distal tubuli lumen diameter of db/þ (G) and db/db (H) where
lumen width is indicated. Quantification of glomerular circumference (I) and distal tubular lumen diameter (J).
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showed no difference between diabetic db/db animals
and controls (Figure 4(C–E)). Furthermore, almost
undetectable levels of pSmad1 were observed in the
PTEC and DTEC compartments in the healthy db/þ
kidneys with no difference in nuclear staining between
the diabetic and non-diabetic group (Figure 4(F–H) and
(I–K), respectively).
A clear BMP ligand and antagonist signature is
present in the diabetic db/db kidney
Based on the altered pSmad signaling signature
observed in the diabetic kidneys, the regulation of a
number of key TGF-b family members were subse-
quently analyzed on the gene level.
RNA was extracted from whole kidneys and a heat-
map displaying real time qPCR of TGF-b family genes
for db/db and db/þmice was generated. Based on 44
genes evaluated, 23 genes were modulated significantly
(Figure 5). db/db kidneys showed significant up-regula-
tion of genes associated with the TGF-b/Activin path-
way such as TGF-b2 (p< .0001) (Figure 6(A)), Activin A
(p< .0001) (Figure 6(B)), and co-receptors of ligands
such as BAMBI (Figure 6(C)) and Betaglycan, an acces-
sory receptor for TGF-b (Figure 6(D)). The fibrotic TGF-b
target gene connective tissue growth factor (CTGF) was
also up-regulated in the diabetic mice (Figure 6(E)), but
interestingly plasminogen activator inhibitor-1 (PAI-1)
was not (Figure 6(F)). In contrast, collagen1a1 was sig-
nificantly down-regulated (Figure 5).
Also BMP subfamily genes normally associated with
activity of pSmad1/5/8 pathway were up-regulated
(Figure 7). BMP ligands such as BMP-2 (p¼ .0052) (Figure
7(A)), BMP-4 (p¼ .0115) (Figure 7(B)), BMP-6 (p¼ .0052)
(Figure 5) and BMP-7 (p¼ .0029) (Figure 7(C)) were
up-regulated in the kidneys of diabetic db/db mice.
Figure 3. pSmad2 immunostaining in db/þ vs. db/db mice. Representative IHC sections from db/þ control mice (A, C, F, I) and
db/db mice (B, D, G, J). Quantification of pSmad2 (E, H, K). (A) and (B) are shown at 40X magnification where the black-
line¼ 50uM. (C) and (D) show a glomeruli structure at 80x magnification, (F) and (G) show a PTEC structure at 80x magnification
and (I) and (J) shows a DTEC structure at 80x magnification. Arrows indicate positively stained nuclei structure indicative of active
signaling. (E) shows glomeruli quantification. (H) and (K) show PTEC and DTEC quantification. Values shown as means ± SEM.
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BMP antagonists such as USAG1 (p¼ .0001) (Figure 7(E)),
Sclerostin (p¼ .0001) (Figure 7(F)), Gremlin1 (p¼ .0003)
(Figure 7(D)) and BMPER (p¼ .0029) (Figure 7(H)) were
also strongly up-regulated, suggesting a dampening
effect on overall BMP induced pSmad1/5/8 in the dia-
betic mice. Chordin-like 1 was decreased in the db/db
animals (Figure 7(G)). The inhibitory Smad proteins
Smad6 and Smad7 (Figure 7(I,J)) were up-regulated in
the db/db mice correlating with lack of regulation of
BMP target gene expression such as ID1 (Figure 7(K)).
The increased expression of BMP antagonists, which are
frequently induced by BMPs, may indicate the occur-
rence of a negative feedback loop.
Taken together, although the db/db mice showed
up-regulation of the TGF-b2 and Activin A ligands that
might contribute to the induction of the target gene
CTGF, this did not lead to up-regulation of other clas-
sical TGF-b regulated genes such as PAI-1 and colla-
gen1a1. Furthermore, the diabetic db/db kidney
showed significant up-regulation of several BMP antag-
onists that might counteract the up-regulation of BMP
target genes despite high ligand expression.
Since Gremlin1 was up-regulated in diabetic db/db
mice (Figure 7(D)), we hypothesized that the increased
level of Gremlin1 within the diabetic animals could
cause a dampening of pSmad1 signaling. Mouse PTEC
cells, TCMK1, were stimulated with mouse BMP-4 and
BMP-7 in the presence of mouse recombinant Gremlin1
protein to test this hypothesis. Here it was shown that
Gremlin1 dose-dependently inhibits both BMP-4 and
BMP-7 induced pSmad1, with the most potent effect on
BMP-4 (Figure 7(L)).
Figure 4. pSmad1/5/8 immunostaining of db/þ vs. db/db mice. Representative IHC sections from db/þ control mice (A, C, F, I)
and STZ mice (B, D, G, J). Quantification of pSmad1/5/8 (E, H, K). (A) and (B) are shown at 40X magnification where the black-
line¼ 50uM. (C) and (D) show a glomerulus structure at 80x magnification, (F) and (G) show a PTEC structure at 80x magnification
and (I) and (J) show a DTEC structure at 80x magnification. Arrows indicate positively stained nuclear structures indicative of
active signaling. (E) shows glomerular pSmad2 quantification. (H) and (K) show PTEC and DTEC quantification. Values are shown
as means ± SEM.
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Discussion
In renal fibrosis, TGF-b family members and down-
stream Smad-dependent and independent pathways
have been suggested to play a major role in tissue
remodeling. In this study, the human DN kidneys
showed up-regulated pSmad2 staining in tubular struc-
tures compared to healthy kidneys. The diabetic tissue
showed an overall increased cytoplasmic expression
and a small increase in pSmad2þ cells within the par-
ietal cells of the Bowman’s capsule. Our results are
important since clinical DN is characterized by a fibrotic
stiffening of the epithelial compartment, possibly due
to dysregulated TGF-b family activity and subsequent
matrix deposition and EMT [36]. Hence the results
obtained herein with the modulated expression pat-
terns of pSmad2 might suggest direct participation of
the TGF-b-family members in T2D-related DN disease
progression.
We observed that human T2D kidneys were very
fibrotic, showing dense and enlarged glomeruli. The
‘type 2-like’ db/db mouse model also showed enlarged
glomeruli and dilated distal tubuli, but did not display
markers of fibrosis. Enlarged glomeruli are possibly a
consequence of hyperfiltration and hypertrophy
whereas dilated tubuli may be a downstream character-
istic of increased albumin filtration. These results sup-
port and extend a study by Ninichuk et al. [37] which
reported the poor translation of the histological find-
ings of tubular atrophy and interstitial fibrosis in db/db
mice compared to humans. Recent reports show that
the nodular sclerotic lesions in glomeruli are only
observed in specific mouse strains with T2D that are
lacking both the leptin gene and the leptin receptor
[38,39]. The db/db mice did, however, show signs of
damage by albuminuria, something others have
described manifesting as late as 23–34weeks of age
[26,40,41]. Many experimental animal models of DN,
including the db/db, only develop characteristics of ear-
lier stages of DN due to the fact that their albumin fil-
tration is increased without a subsequent decline in
Glomerular Filtration Rate (GFR). We have previously
confirmed this in house at our facility by conducting
extensive measurement of both serum and urine inulin
and creatinine without finding any decline in GFR for
the time span tested in this study. Hence, differences in
disease manifestation between mouse models and
patients can be explained by a variety of different fac-
tors, where a very different time course of disease pro-
gression seems to complicate translation and should be
addressed in preclinical development of therapeutic
targets.
The elevated levels of pSmad2 observed in disease
of the human kidney led us to study the translation to
the experimental model of T2D-related DN, the db/db
mouse. Surprisingly, db/db mice showed an opposite
pSmad2 staining signature compared to what was
observed in human T2D DN. Diabetic mouse kidneys
showed significantly decreased pSmad2 staining within
the PTECs. Not only did our results reveal a poor transla-
tion from the diabetic patient to the pre-clinical model
with regards to molecular pSmad2 signature expression,
but also the only minimal evidence of fibrotic changes
found in the mice. It has been suggested that Smad2
signaling is anti-fibrotic and renoprotective, while it is
Smad3 that is the pro-fibrotic factor [42,43]. Results on
Smad staining within the field of kidney fibrosis are
contradictory, which we suggest can be due to different
mouse strains and the use of different anti-Smad anti-
bodies directed against either phospho-Smad or Smad
Figure 5. Heat map of expression of genes in the TGF-b fam-
ily regulated in db/db animals vs. db/þ controls at 15weeks
of age. Values correspond to deltaCT values and in the online
version of the manuscript the color coding corresponds to the
relative expression in db/þ and db/db. High gene expression
(a low deltaCT) is shown in green whereas low gene expres-
sion (a high deltaCT) is shown in red. Genes are ordered
based on p values. The false discovery rate (Fdr) was set at
.05 corresponding to a p values of .024.
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showing different affinity and degree of cross-reactivity.
We see the advantage of adding our findings with an
actual activated Smad staining with a validated anti-
body to the field that has no cross-reaction to other
phosphorylated Smads on immunoprecipitation (see
the ‘Methods’ section). We used pSmad2 staining to
evaluate overall TGF-b activity in kidneys from patients
and mouse model and downstream profibrotic gene
expression to evaluate effect on fibrotic pathways in
the mouse model.
T2D patients show up-regulated PAI-1 gene levels
[44], whereas we did not observe expression changes in
the db/db mice. This is despite the fact that ligands
such as Activin A and TGF-b2, both thought to mediate
pSmad2/3 signaling, were up-regulated in the diabetic
db/db kidney. In another model of fibrotic kidney dis-
ease, unilateral ureteral obstruction, Activin A has previ-
ously been reported up-regulated locally in tubular cells
were it was speculated to act as a paracrine factor acti-
vating renal interstitial fibroblasts in the kidney to pro-
duce collagen and a-SMA [45]. While TGF-b2 was
up-regulated in db/db tissue on gene level, TGF-b1 was
surprisingly not up-regulated. There is a great redun-
dancy between the TGF-b-ligands as all TGF-b isoforms
has been reported to induce fibrosis [46]. The role of
the different TGF-b isoforms in T2D associated DN is still
not fully understood and many studies report, unlike
our db/db data, TGF-b1 to be up-regulated in the glom-
erulus and in the cortical tubules [47,48].
Despite ligands favoring activation of the Smad2/3
pathway being up-regulated, the analysis of the TGF-b
family on a gene level showed strong up-regulation of
antagonists of the pSmad2 pathway: BAMBI, a TGF-b
family antagonist was up-regulated in diabetic mice vs.
controls. Furthermore, Betaglycan, a co-receptor of all
TGF-b isoforms, but especially important for TGF-b2 and
TGFbRII assembly, was also up-regulated in db/db mice,
Betaglycan was also up-regulated in mice 15weeks of
age. However, in some studies Betaglycan has an inhibi-
tory effect to TGF-b signaling which might contribute to
the lack of pSmad2 evidenced in db/db [49,50]. Studies
in db/db have shown that soluble Betaglycan reduce
the expression of all TGF-b isoforms and additionally
reduce the kidney levels of collagen IV and fibronectin
[51]. Hence, even though CTGF, a downstream target of
TGF-b, was up-regulated, the fibrotic PAI-1 was not up-
regulated, correlating with absent regulation of colla-
gens and extracellular matrix found in the diabetic mice
(neither on gene level or protein level with histology).
This could suggest a limited role of TGF-b induced
fibrotic events in the db/db model of DN.
Translation between human disease and pre-clinical
models has been a challenge for many diseases and
particularly for DN [34]. Most focus concerning the role
of TGF-b family in DN has been on TGF-b1 and BMP-7,
and to our knowledge, limited literature exists on the
remaining part of the BMPs within DN. The level of
pSmad1 was not examined in the human samples of
Figure 6. Expression of genes encoding modifiers of pSmad signaling in 15weeks old db/db mice. (A) TGF-b2; (B) Activin A;
(C) BAMBI; (D) Betaglycan; (E) CTGF; and (F) PAI-1. Values are relative mRNA levels corrected to housekeeping genes and displayed
as boxes with whiskers showing minimum to maximum for a group of 10 mice.
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this study, but other groups have reported contradict-
ory results within this field. Turk et al. [52] has reported
less pSmad1/5/8 in progressed human DN, while Abe
et al. [53] has reported up-regulated Smad1 in
advanced DN. The diabetic mice of this current study
did not show any difference of pSmad1/5/8 protein
expression even though several BMP ligands were up-
regulated. In contrast, Smad1 expression was shown to
correlate with the severity of mesangial matrix expan-
sion in STZ-treated Sprague–Dawley rats [54], and simi-
lar to our study, Matsubara et al. [55] also found several
BMP ligands up-regulated in STZ mice on a C57BL/6 J
background. It is possible that we looked at a too early
time point in db/db renal disease progression or that
the db/db model simply does not show the same
pSmad patterns as the STZ model. Alternatively, the
unchanged level of pSmad1 may be explained by up-
regulation of BMP antagonists such as Gremlin1,
Sclerostin, USAG1 and BMPER, which were all induced in
the kidneys of db/db mice. The role of these antago-
nists is to control BMP signaling, frequently as part of a
negative feedback loop. In line with this, the down-
stream BMP target ID1 was not regulated.
Gremlin1 is an antagonist of BMP-2, BMP-4 and
BMP7, which heterodimerizes with the ligands and
thereby prevents them from binding to their receptors
[56]. Patients with severe DN show high expression of
Gremlin1 in tubular epithelial cells [57] where
Figure 7. Expression genes encoding modifiers of pSmad signaling in 15weeks old db/db mice. (A) BMP-2; (B) BMP-4; (C) BMP-7;
(D) Gremlin1; (E) USAG-1; (F) Sclerostin; (G) Chordin-like 1; (H) BMPER; (I) Smad6; (J) Smad7; and (K) ID-1. Values are relative mRNA
levels corrected to housekeeping genes and shown as box with whiskers minimum to maximum for a group of 10 mice.
(L) Recombinant mouse Gremlin1 dose-dependent inhibition of BMP4 (4 ng/ml) and BMP7 (150 ng/ml) induced pSmad1 activity,
quantified by AlhaLISA Surefire assay showing means ± SEM of n¼ 4.
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expression correlates with tubulointerstitial damage
and elevated serum creatinine levels [58]. Interestingly,
transgenic STZ mouse expressing human Gremlin1 in
PTECs show greater glomerular and tubulointerstitial
injury [59] and heterozygous Gremlin1 knockout mice
ameliorates renal damage [59]. We showed that recom-
binant mouse Gremlin1 was able to inhibit pSmad1 sig-
nal in BMP-4 and BMP-7 stimulated mouse PTECs,
which therefore, could present a mechanistic explan-
ation for the lack of increased pSmad1 despite
increased BMP-2, -4 and -7.
Conclusions
Fibrotic disease represents one of the largest groups of
disorders for which there is no effective therapy and
thus proving a major unmet medical need. T2D associ-
ated DN has not been given the same attention as T1D
due to the complexity of disease causality. This study
provides new insights into DN and the regulation of
TGF-b family members in a classical pre-clinical T2D
model. In summary, translation of the development of
fibrosis and DN between T2D patients and the ‘type-2’-
like experimental pre-clinical model, db/db mice is poor
on a macroscopic as well as on a molecular level,
emphasizing that the choice of preclinical model should
be considered carefully. The current study provides
important new information on the role of TGF-b family
regulation and highlights that monitoring signaling
events and TGF-b family expression patterns could be
useful as biomarkers or as pharmaceutical target in DN.
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